Aptus Capital Advisors LLC Buys 265,468 Shares of Bristol-Myers Squibb (NYSE:BMY)

Aptus Capital Advisors LLC boosted its holdings in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 1,221.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 287,206 shares of the biopharmaceutical company's stock after acquiring an additional 265,468 shares during the period. Aptus Capital Advisors LLC's holdings in Bristol-Myers Squibb were worth $16,244,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in BMY. Norges Bank acquired a new position in shares of Bristol-Myers Squibb in the fourth quarter valued at approximately $1,989,525,000. Wellington Management Group LLP grew its stake in Bristol-Myers Squibb by 3,880.0% in the 4th quarter. Wellington Management Group LLP now owns 5,977,505 shares of the biopharmaceutical company's stock valued at $338,088,000 after purchasing an additional 5,827,317 shares during the period. Raymond James Financial Inc. purchased a new position in shares of Bristol-Myers Squibb in the 4th quarter worth about $257,618,000. Schroder Investment Management Group increased its holdings in Bristol-Myers Squibb by 49.7% in the 4th quarter. Schroder Investment Management Group now owns 11,413,428 shares of the biopharmaceutical company's stock worth $639,837,000 after acquiring an additional 3,787,075 shares during the last quarter. Finally, Northern Trust Corp increased its position in shares of Bristol-Myers Squibb by 16.2% during the fourth quarter. Northern Trust Corp now owns 24,658,360 shares of the biopharmaceutical company's stock valued at $1,394,677,000 after buying an additional 3,431,248 shares during the period. 76.41% of the stock is owned by institutional investors and hedge funds.

Bristol-Myers Squibb Trading Down 1.2 %

Shares of Bristol-Myers Squibb stock traded down $0.55 during trading hours on Thursday, hitting $47.07. The company's stock had a trading volume of 12,577,756 shares, compared to its average volume of 13,025,418. Bristol-Myers Squibb has a 1-year low of $39.35 and a 1-year high of $63.33. The business has a fifty day moving average of $55.06 and a 200 day moving average of $56.27. The company has a quick ratio of 1.15, a current ratio of 1.25 and a debt-to-equity ratio of 2.90. The company has a market capitalization of $95.79 billion, a PE ratio of -10.65, a P/E/G ratio of 2.07 and a beta of 0.39.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, beating analysts' consensus estimates of $1.50 by $0.30. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The business had revenue of $11.20 billion during the quarter, compared to the consensus estimate of $10.77 billion. During the same quarter in the prior year, the firm earned ($4.40) EPS. The company's revenue for the quarter was down 5.6% compared to the same quarter last year. As a group, equities analysts forecast that Bristol-Myers Squibb will post 6.74 EPS for the current year.

Bristol-Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Thursday, May 1st. Investors of record on Friday, April 4th were issued a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.27%. The ex-dividend date was Friday, April 4th. Bristol-Myers Squibb's payout ratio is 92.88%.

Insider Activity at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, EVP Samit Hirawat acquired 4,250 shares of the firm's stock in a transaction on Friday, April 25th. The stock was purchased at an average cost of $47.58 per share, for a total transaction of $202,215.00. Following the transaction, the executive vice president now owns 83,513 shares of the company's stock, valued at $3,973,548.54. The trade was a 5.36 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.09% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of research analysts have weighed in on BMY shares. Truist Financial upped their target price on Bristol-Myers Squibb from $62.00 to $65.00 and gave the stock a "buy" rating in a report on Wednesday, January 8th. Citigroup boosted their target price on shares of Bristol-Myers Squibb from $60.00 to $65.00 and gave the stock a "neutral" rating in a report on Tuesday, January 28th. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $55.00 target price on shares of Bristol-Myers Squibb in a research note on Tuesday, April 22nd. Jefferies Financial Group cut their price target on Bristol-Myers Squibb from $70.00 to $68.00 and set a "buy" rating on the stock in a research note on Wednesday, April 23rd. Finally, Argus upgraded Bristol-Myers Squibb to a "hold" rating in a report on Friday, April 25th. Two analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have assigned a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $58.00.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.